Background/Aims: This case series presents the novel Genetic Addiction Risk Score (GARS®) coupled with a customized pro-dopamine regulator matched to polymorphic reward genes having a hypodopaminergic risk.

Methods: The proband is a female with a history of drug abuse and alcoholism. She experienced a car accident under the influence and voluntarily entered treatment. Following an assessment, she was genotyped using the GARS, and started a neuronutrient with a KB220 base indicated by the identified polymorphisms. She began taking it in April 2018 and continues.

Results: She had success in recovery from Substance Use Disorder (SUD) and improvement in socialization, family, economic status, well-being, and attenuation of Major Depression. She tested negative over the first two months in treatment and a recent screening. After approximately two months, her parents also decided to take the GARS and started taking the recommended variants. The proband’s father (a binge drinker) and mother (no SUD) both showed improvement in various behavioral issues. Finally, the proband’s biological children were also GARS tested, showing a high risk for SUD.

Conclusion: This three-generation case series represents an example of the impact of genetic information coupled with an appropriate DNA guided “Pro-Dopamine Regulator” in recovery and enhancement of life.

背景/目的：本病例系列介绍了新颖的遗传成瘾风险评分（GARS®），以及与具有低多巴胺能风险的多态性奖励基因相匹配的定制前多巴胺调节剂。

方法：先证者为女性，有吸毒和酗酒史。她在此影响下发生了车祸，并自愿接受治疗。经过评估后，使用GARS对她进行了基因分型，并通过鉴定出的多态性表明了其具有KB220碱基的神经营养。她于2018年4月开始服用，并一直持续下去。

结果：她成功地从物质使用障碍（SUD）中恢复过来，并在社交，家庭，经济状况，幸福感以及重度抑郁症的缓解方面得到了改善。在治疗的前两个月和最近的筛查中，她的测试结果均为阴性。大约两个月后，她的父母还决定采用GARS，并开始采用推荐的变体。先证者的父亲（狂饮者）和母亲（没有SUD）在各种行为问题上均表现出改善。最后，先证者的亲生子女也接受了GARS测试，显示出SUD的高风险。

结论：这个三代病例系列代表了遗传信息与适当的DNA指导的“多巴胺调节剂”在恢复和延长生命中的影响的一个例子。